Patients implanted with the CoreValve transcatheter aortic valve replacement showed strong blood flow and improved quality of life at five years post-implant, according to results from two Medtronic ...
On Sunday, Medtronic published five-year data from a low-risk clinical trial of its Evolut transcatheter aortic valve replacement (TAVR) system. In the trial, TAVR, which assists patients suffering ...
Upgraded Medtronic to a ‘Buy’ rating with a fair value of $105 per share, driven by strong growth in Cardiac Ablation Solutions and TAVR markets. Medtronic reported 4.1% organic revenue growth and 6.2 ...
Minneapolis-based Medtronic will appeal the Federal District Court of Delaware’s preliminary injuction granted to Irvine, Calif.-based Edwards Lifesciences. The Court issued the preliminary injunction ...
TAVR is a minimally invasive procedure that replaces the aortic valve using a catheter-based approach, eliminating the need for open-heart surgery. Initially approved for high-risk patients, TAVR is ...
WASHINGTON, DC — (Updated with commentary) The SURTAVI trial hit its noninferiority end point, making it the second prospective randomized trial to show transcatheter aortic-valve replacement (TAVR) ...
On Sunday, Medtronic published five-year data from a low-risk clinical trial of its Evolut transcatheter aortic valve replacement (TAVR) system. Start Your Mornings Smarter! Wake up with Breakfast ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback